Trial Profile
Multicenter prospective randomized open with a blinded end point (PROBE) parallel-group study on treatment with biphasic insulin BIAsp70/30 and short-acting insulin or rapid-acting analogue plus glargine in comparison with short-acting insulin or rapidacting analogue plus glargine to evaluate the metabolic control and quality of life (QoL) in children and adolescents with type 1 diabetes mellitus over 12 months
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 27 Mar 2012
Price :
$35
*
At a glance
- Drugs Insulin aspart/insulin protamine aspart (Primary) ; Insulin aspart; Insulin glargine
- Indications Type 1 diabetes mellitus
- Focus Therapeutic Use
- 27 Mar 2012 New trial record